Harvard Bioscience, Inc. (HBIO)
| Market Cap | 31.37M +82.4% |
| Revenue (ttm) | 86.55M -8.1% |
| Net Income | -56.70M |
| EPS | -12.80 |
| Shares Out | 4.51M |
| PE Ratio | n/a |
| Forward PE | 36.29 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 23,255 |
| Open | 6.90 |
| Previous Close | 6.90 |
| Day's Range | 6.85 - 7.15 |
| 52-Week Range | n/a |
| Beta | 1.57 |
| Analysts | Buy |
| Price Target | 18.00 (+158.81%) |
| Earnings Date | May 12, 2026 |
About HBIO
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including d... [Read more]
Financial Performance
In 2025, Harvard Bioscience's revenue was $86.55 million, a decrease of -8.06% compared to the previous year's $94.14 million. Losses were -$56.70 million, 357.1% more than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for HBIO stock is "Buy." The 12-month stock price target is $18.0, which is an increase of 158.81% from the latest price.
News
Harvard Bioscience to Participate in Upcoming Investor Conferences
HOLLISTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced Chief Executive Officer, John Duke and Chief Financial Officer, Mark Frost's participation in...
Harvard Bioscience Schedules First Quarter 2026 Earnings Conference Call for May 12, 2026 at 8:00 AM ET
HOLLISTON, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended March 31, 2026, before the market opens on May 12...
Harvard Bioscience Transcript: 2026 KeyBanc Capital Markets Healthcare Forum
Leadership is focused on innovation and operational efficiency, targeting high-growth areas like organoids and bioproduction. Financials are strong with improved margins, reduced debt service, and new products expected to double their revenue share. Academic, pharma, and CRO markets are key segments, with Asia showing recovery.
Harvard Bioscience price target adjusted to $6 at Benchmark after reverse split
Benchmark analyst Bruce Jackson raised the firm’s price target on Harvard Bioscience (HBIO) to $6 from 60c and keeps a Speculative Buy rating on the shares after updating the firm’s…
Harvard Bioscience trading halted, news pending
19:50 EDT Harvard Bioscience (HBIO) trading halted, news pending
Harvard Bioscience price target lowered to 60c from $2 at Benchmark
Benchmark lowered the firm’s price target on Harvard Bioscience (HBIO) to 60c from $2 and keeps a Speculative Buy rating on the shares. The timing of recovery continues to be…
Harvard Bioscience Earnings Call Transcript: Q4 2025
2025 saw foundational restructuring, improved margins, and a strategic pivot to translational science. Despite revenue declines from tariffs and NIH delays, cost actions drove EBITDA growth. 2026 guidance calls for modest revenue and margin gains, with NPI and Asia Pacific recovery supporting growth.
Harvard Bioscience reports Q4 adjusted EPS (0c) vs 6c last year
Reports Q4 revenue $23.735M vs $24.556M last year. “2025 was a pivotal year for Harvard Bioscience (HBIO) as we strengthened our balance sheet and streamlined our operating model. This culminated…
Harvard Bioscience appoints interim CFO Mark Frost as CFO
Interim CFO Mark Frost Appointed CFO on Permanent Basis
Harvard Bioscience sees Q1 revenue $20M-$22M
The Company expects: Adjusted EBITDA between $1.0 million and $2.2 million
Harvard Bioscience sees FY26 revenue growth 2%-4%
Full Year 2026 Guidance : Adjusted EBITDA growth between 6% and 10%.
Harvard Bioscience Announces Fourth Quarter and Full-Year 2025 Financial Results
Fourth Quarter 2025 Revenues of $23.7M and Gross Margin of 59.7% Full Year 2025 Revenues of $86.6M and Gross Margin of 57.7% Interim CFO Mark Frost Appointed CFO on Permanent Basis Introduces Full Yea...
Harvard Bioscience announces 1-for-10 reverse stock split
Harvard Bioscience (HBIO) announced that its board of directors approved the company’s 1-for-10 reverse stock split of the it’s common stock. The reverse split was approved by the stockholders of…
Harvard Bioscience Announces Reverse Stock Split
Harvard Bioscience's common stock is expected to begin trading on a post-split adjusted basis on March 16, 2026 HOLLISTON, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: H...
Harvard Bioscience Transcript: EGM 2026
Stockholders approved both the reverse stock split amendment and the adjournment proposal with over 97% support. Final results will be published in a Form 8-K, and any submitted questions will be answered separately.
Harvard Bioscience to Participate in KeyBanc's Virtual Healthcare Forum
HOLLISTON, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that John Duke, President and Chief Executive Officer, and Mark Frost, Interim Chief Financ...
Harvard Bioscience Schedules Fourth Quarter 2025 Earnings Conference Call for March 12, 2026 at 8:00 AM ET
HOLLISTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended December 31, 2025, before the market opens on Marc...
Harvard Bioscience outlines strategy for growth
The company said, “As the life sciences industry accelerates toward New Approach Methodologies, Harvard Bioscience (HBIO) is evolving from a traditional tools provider into a leading enabler of Transl...
Harvard Bioscience reports preliminary Q4 revenue $23.7M
Gross Margin of 60%, at the high end of the 58% to 60% guidance range, driven by an improved mix to higher margin product lines, as well as the benefit…
Harvard Bioscience Announces Preliminary Fourth Quarter Financial Results, Positive Outlook for 2026 & Outlines Long-Term Strategic Focus Areas
Reports preliminary fourth quarter revenue in line with guidance, gross margin at high end of guidance, and strong year over year adjusted EBITDA performance Expects year over year revenue growth and ...
Harvard Bioscience files to sell 9.5M shares of common stock for holders
17:04 EST Harvard Bioscience (HBIO) files to sell 9.5M shares of common stock for holders
Harvard Bioscience closes manufacturing operations in Massachusetts
Harvard Bioscience (HBIO) announced a strategic consolidation of its manufacturing operations. The company will close its manufacturing facility in Holliston, Massachusetts and transition U.S. product...
Harvard Bioscience Announces Strategic Consolidation of Manufacturing Operations to Improve Efficiency and Support Long-Term Growth
Streamlining production footprint and improving manufacturing efficiency through phased closure of Holliston, MA plant Initiative expected to deliver approximately $3 million in cost savings in 2027 ...
Harvard Bioscience enters agreement with BroadOak Capital Partners
Harvard Bioscience (HBIO) entered into an agreement with BroadOak Capital Partners to provide a $40M credit facility comprised of three term loans, all of which will be funded on December…
Harvard Bioscience Announces the Successful Completion of Debt Refinancing with Comprehensive Growth Financing Package
Completes Repayment of Existing Credit Agreement, Extends Debt Maturity, and Enhances Financial Flexibility BroadOak Partner Bill Snider to Join Board of Directors and Company to Form Advisory Board o...